A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
iOnctura
City of Hope Medical Center
City of Hope Medical Center
Mayo Clinic
American Regent, Inc.
Newave Pharmaceutical Inc
City of Hope Medical Center
OHSU Knight Cancer Institute
Dartmouth-Hitchcock Medical Center
Prelude Therapeutics
University of Rochester
Medigene AG
H. Lee Moffitt Cancer Center and Research Institute
Case Comprehensive Cancer Center
Tarix Pharmaceuticals
Case Comprehensive Cancer Center
University of Pittsburgh
Stanford University
Wake Forest University Health Sciences
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
California Cancer Consortium
Massachusetts General Hospital
University of Louisville
Yale University
Prescient Therapeutics, Ltd.
Alliance for Clinical Trials in Oncology
City of Hope Medical Center
National Cancer Institute (NCI)
Children's Oncology Group
Indiana University
Indiana University
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Millennium Pharmaceuticals, Inc.
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Northwestern University
Northwestern University
National Institutes of Health Clinical Center (CC)